Study of a Non-invasive Glucose Measuring Device

Inclusion criteria

• Male or female subject ≥18 years.
• Subject with type 2 diabetes.
• Signed informed consent form (ICF).

Exclusion criteria

• Individual treated with intensified insulin treatment.
• Sodium, Potassium. Creatinine, eGFR, and ALAT (more than three times the upper limit of normal range).
• Clinically relevant anaemia or thrombocytopenia.
• Infection with hepatitis B, C or HIV (if subject participates in subprotocol 1).
• Intake of anticoagulant medication (with the exception of acetylsalicylic acid, ASS 100).
• For female subjects: Pregnancy or breastfeeding or lack of a negative pregnancy test (except in case of menopause, sterilization, or hysterectomy).
• Subjects not able to understand and read local language.
• Cognitive impairment, or in investigator's opinion, subject is not able to follow instructions provided and as specified in the clinical investigation plan (CIP).
• Subject not able to hold hand/arm steady (including tremors and Parkinson's Disease).
• Skin changes, tattoos, or diseases on right thenar (measurement site).
• Reduced circulation in right hand evaluated by Allen's test.
• Known allergy to medical grade alcohol.
• Haemodialysis.
• Topical administration of glucocorticoids at the right hand for the past 7 days or during the study period.
• Any disorder, which in the investigator's opinion, might jeopardise subject's safety or compliance with the CIP.
• Any incapacity or general condition that, in the opinion of the investigator, prevents adequate compliance with the study procedures, e.g., mental, or visual incapacity, language barriers, alcohol or drug abuse.
• Dependency from the sponsor or the clinical investigator (e.g., co-workers of the sponsor, the study site, and/ or their families).
• Subjects currently participating in another study.